RECRUITING

HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry

Talk to us

Conditions

Heart FailurePulmonary Artery (PA) pressure monitor

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the HF2 (Hemodynamic Frontiers in Heart Failure) registry is to collect relevant patient-level demographic, clinical, laboratory, and hemodynamic data from patients implanted with pulmonary artery pressure sensor at participating centers to advance scientific knowledge about ambulatory hemodynamics monitoring and HF (Heart Failure) therapies. The data collected will be used for retrospective studies, quality improvement, identifying research cohorts, and member-initiated research.

Official Title

Hemodynamic Frontiers in Heart Failure Registry

Quick Facts

Study Start:2022-10-21
Study Completion:2030-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06425848

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 100 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. All patients would have been or will be implanted per indications from FDA approval/CHAMPION trial. These would be patients with NYHA (New York Heart Association) Class III heart failure who had a prior hospitalization.
  2. 2. Patients who meet the expanded FDA indication (BNP elevation without hospitalization or NYHA class II).
  1. 1. Patients less than 18 years of age.
  2. 2. Pregnant women at the scheduled time of PA pressure sensor implant.
  3. 3. Patients unable or unwilling to have continuity of care in the heart failure clinic.

Contacts and Locations

Study Contact

Kartik Munshi, MPH
CONTACT
913-945-6445
kmunshi@kumc.edu

Principal Investigator

Hirak Shah, MD
PRINCIPAL_INVESTIGATOR
University of Kansas Medical Center

Study Locations (Sites)

Scripps Health
La Jolla, California, 92037
United States
Indiana University
Bloomington, Indiana, 47401
United States
University of Kansas Medical Center
Kansas City, Kansas, 66160
United States
Fairview Health
Maplewood, Minnesota, 55109
United States
Minneapolis Heart Institute Foundation/ Allina Health
Minneapolis, Minnesota, 55407
United States
Saint Luke's Health System
Kansas City, Missouri, 64131
United States
University of North Carolina/ Rex Hospital, Inc.
Raleigh, North Carolina, 27607
United States
Providence Heart Institute
Portland, Oregon, 97225
United States
Prisma Health
Columbia, South Carolina, 29203
United States
Sanford Health
Sioux Falls, South Dakota, 57104
United States
Austin Heart
Austin, Texas, 78756
United States
Houston Methodist DeBakey Heart and Vascular Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: University of Kansas Medical Center

  • Hirak Shah, MD, PRINCIPAL_INVESTIGATOR, University of Kansas Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-10-21
Study Completion Date2030-12-31

Study Record Updates

Study Start Date2022-10-21
Study Completion Date2030-12-31

Terms related to this study

Keywords Provided by Researchers

  • Pulmonary Artery (PA) pressure monitor

Additional Relevant MeSH Terms

  • Heart Failure